An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis

Wyeth is now a wholly owned subsidiary of Pfizer0 sites149 target enrollmentApril 2001

ConditionsPeptic Ulcer Hemorrhage

DrugsPantoprazole

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Peptic Ulcer Hemorrhage
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 149
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous pantoprazole in the prevention of rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.

Registry

clinicaltrials.gov

Start Date

April 2001

End Date

January 2003

Last Updated

13 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients must be men or non-pregnant women at least 18 years of age
•Patients who present with a gastric or duodenal ulcer

Exclusion Criteria

•Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation
•Patients presenting with active bleeding and/or NBVV at 2 or more separate sites
•Patients with any severe concomitant diseases, eg, end stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases